NCT04247815View on ClinicalTrials.gov

Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 16, 2020

Primary Completion Date

February 4, 2021

Study Completion Date

February 4, 2021

Conditions
Rheumatoid Arthritis
Interventions
DRUG

ATI-450

Oral, small molecule MK2 inhibitor

DRUG

Placebo oral tablet

Placebo tablet manufactured to match ATI-450 in appearance

DRUG

Methotrexate

7.5 mg to 25 mg weekly

Trial Locations (5)

16635

Aclaris Investigational Site, Duncansville

30342

Aclaris Investigational Site, Atlanta

33613

Aclaris Investigational Site, Tampa

36207

Aclaris Investigational Site, Anniston

75150

Aclaris Investigational Site, Mesquite

Sponsors
All Listed Sponsors
lead

Aclaris Therapeutics, Inc.

INDUSTRY

NCT04247815 - Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RA | Biotech Hunter | Biotech Hunter